Hancock Jaffe Laboratories Inc. (NASDAQ: HJLI) Receives Breakthrough Device Designation From FDA for VenoValve

Hancock Jaffe Laboratories Inc. (NASDAQ: HJLI) has announced that the US  FDA has granted VenoValve Breakthrough Device Designation. VenoValve is Hancock Jaffe’s flagship product expected to commence a pivotal trial in the US. The FDA’s Breakthrough Devices Program was created to allow devices offering effective treatment or diagnosis of life-threatening or irreversibly disabling diseases or disorders to receive priority evaluation.

VenValve treats Chronic Venous Insufficiency 

The VenoValve could be used to treat Chronic Venous Insufficiency (CVI), a disorder that affects about 2.4 million people in the United States. CVI develops when the valves inside the leg’s veins fail, allowing blood to flow in the wrong direction and increasing pressure inside the veins (venous hypertension). Notably, CVI is a severe disorder that makes simple actions like sleeping, washing, and walking difficult for individuals. Unfortunately, deep venous CVI presently has no viable therapies.

Hancock Jaffe Robert Berman said, “We are very pleased to have the opportunity to work with the FDA on an expedited basis as we try to bring relief to the millions of patients who suffer from deep venous CVI and who currently have no effective treatment options. The VenoValve significantly improved the lives of the patients in our first-in-human study, and we hope to replicate that success in our SAVVE U.S. clinical trial.”

Patient reflux improvement was 54%

The average patient improvement in reflux was 54%, the average improvement in disease manifestations was 56%, and an average improvement in pain was 76%, according to data from the VenoValve first-in-human study, which was presented in December 2020. Furthermore, at 30 days after VenoValve implantation, there weren’t any material adverse events (MAEs) observed.

The primary endpoints for  SAVVE U.S. pivotal trial will be the same as for the first-in-human trial: the primary safety endpoint will be the MAE  occurrence is around 10% of patients 30 days after VenoValve implantation. The primary efficacy endpoint will be reflux improvement similar to or greater than 30% six months after VenoValve surgery.